AstraZeneca has adopted LeadScope's technology to facilitate the evaluation of its high throughput screening campaigns. The software is a wise investment for AZ, in that it enables comparison of newly generated HTS data with data from multiple sources. This should help speed AZ's early phase research decisions.
European pharma company AstraZeneca (AZ) has licensed LeadScope's Enterprise software and ToxScope databases, which it will use to speed the drug discovery process by managing the data generated by the company's high throughput screening (HTS) initiatives. The system should help researchers to identify correlations between biological information and structural features of chemical libraries.
LeadScope says that its ToxScope databases include data on acute toxicity, hepatotoxicity, mutagenicity and carcinogenicity. As a result, its users can immediately compare the results of efficacy screening and toxicity information. LeadScope's system also allows customers to use structural alerts from any source and explore the chemical space of any data set.
"We have found LeadScope Enterprise to be very useful in rapidly identifying correlations between chemical structural features and biological activity, thereby improving the quality of research decisions in the early HTS evaluation phase", commented AstraZeneca's Christer Westerlund.
This is important because, as the use of high throughput screening creates an increasing data burden, pharmaceutical companies must find technologies that are able to manage and make use of data from multiple sources, allowing for integration with existing databases. The ToxScope software is a wise investment for AstraZeneca, since it will allow the company easily to compare newly generated data with data from multiple sources.